Connect with others who understand.

  •   Learn from expert-reviewed resources
  •   Real advice from people who’ve been there
  •   People who understand what you’re going through
Sign Up Log In
All Resources Treatments A-Z Personal Assistant Help Center Crisis
Powered By
Real members of MyBCTeam have posted questions and answers that support our community guidelines, and should not be taken as medical advice. Looking for the latest medically reviewed content by doctors and experts? Visit our resource section.

The FDA has approved new hormone positive drugs for bc. Anyone using them? November, 2026 one expected for early stage ER+. Following.

A MyBCTeam Member asked a question 💭
Winter Haven, FL
July 11
 · 
Reactions
A MyBCTeam Member

Just looked it up- it is made by Genentech (the same company that does Herceptin). I was able to get co-pay assistance for Herceptin, so looked it up, apparently giredestrant would qualify for the program (which can offset costs by up to $25.000 a calendar year.

Putting the link below, should anyone want to consider, and need to learn if they might qualify for the program:

https://www.copayassistancenow.com/

Patient Saving Program
https://www.copayassistancenow.com/
July 11
A MyBCTeam Member

There is new hormone blocker, giredestrant. I am told it is supposed to a lot better for side effects, but is very, very expensive.

July 11
MyBCTeam

It's great that you're staying on top of new developments — that kind of proactive approach really matters! There have indeed been some exciting recent approvals for hormone receptor-positive (HR+) breast cancer.

Here are some of the newer FDA-approved options:

- Capivasertib + Fulvestrant (Truqap) — Approved in 2023 for Show Full Answer

It's great that you're staying on top of new developments — that kind of proactive approach really matters! There have indeed been some exciting recent approvals for hormone receptor-positive (HR+) breast cancer.

Here are some of the newer FDA-approved options:

- Capivasertib + Fulvestrant (Truqap) — Approved in 2023 for HR+/HER2-negative breast cancer, particularly for those with certain mutations who've already tried other treatments
- Sacituzumab govitecan (Trodelvy) — Also approved in 2023 for HR+/HER2-negative breast cancer that has progressed after other therapies
- Imlunestrant (Inluriyo) — A newer SERD that targets estrogen receptors

CDK4/6 inhibitors like palbociclib (Ibrance), ribociclib (Kisqali), and abemaciclib (Verzenio) continue to be widely used alongside hormone therapy for HR+ cases. Many MyBCTeam members are actively discussing these newer treatments and sharing their experiences. It's always worth asking your oncologist whether any of these options — or upcoming clinical trials — might be right for your specific situation, especially as new approvals are on the horizon!

July 11
A MyBCTeam Member

I am not looking forward to doubling up drugs because it feels, emphasis on that word, like it with be twice the side effects but I know I wont know until I try. In my personal experience I have found that its important to acknowledge the feels. But not get bogged down in them and move on. Feelings are just part of my being. My intelect and science knowledge and experience are important too.

July 11

Related Questions

View All

Key breast cancer developments in early 2026

A MyBCTeam Member asked a question 💭
Rochester, NY
April 24

NanoKnife for Breast Cancer

A MyBCTeam Member asked a question 💭
Rochester, NY
December 29, 2025

How Early-Stage HER2-Positive Breast Cancer Treatment Has Evolved
6 HER2-Positive Breast Cancer Symptoms and Early Signs
Kadcyle Extends Survival for Early HER2-Positive Breast Cancer
Continue with Facebook
Continue with Google
By joining, you accept our Terms of Use, and acknowledge our collection, sharing, and use of your data in accordance with our Health Data and Privacy policies.
Already a member? Log In